Tricuspid regurgitation epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) (Created page with "{{CMG}} ==Overview== ==References== {{Reflist|2}} Category:Valvular heart disease Category:Cardiology Category:Disease Category:Cardiac surgery Category:O...") |
Rim Halaby (talk | contribs) |
||
| Line 2: | Line 2: | ||
==Overview== | ==Overview== | ||
==Prevalence== | |||
The Framingham Heart Study, a prospective epidemiologic study, evaluated the [[prevalence]] and severity of TR and other valvular diseases by color [[Doppler]] examinations in 1,696 men and 1,893 women. The study revealed that TR is the second most common valvular regurgitation in the general population, after [[mitral regurgitation]]. The prevalence of TR (with a severity ranging from trace to moderate regurgitation) was 82% in men and 85.7% in women. When trace regurgitation is excluded, the prevalence of TR of a severity ≥ mild was 14.8% in men and 18.4% in women. The elevated prevalence of trace regurgitation can be a normal finding related to an artifact or an anatomic characteristic of the closure of the [[tricuspid valve]].<ref name="pmid10190406">{{cite journal| author=Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL et al.| title=Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study) | journal=Am J Cardiol | year= 1999 | volume= 83 | issue= 6 | pages= 897-902 | pmid=10190406 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10190406 }} </ref> | |||
==Age== | |||
The prevalence of TR increases with age. Shown below are tables depicting the prevalence of MR by age and severity in men and women according the results of the Framingham Heart Study.<ref name="pmid10190406">{{cite journal| author=Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL et al.| title=Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study) | journal=Am J Cardiol | year= 1999 | volume= 83 | issue= 6 | pages= 897-902 | pmid=10190406 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10190406 }} </ref> | |||
{| | |||
|- | |||
|style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center | '''Severity of TR''' ||style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center colspan= 5|'''Prevalence of TR by age in men''' | |||
|- | |||
|style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center | ||style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center | '''26-29''' ||style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center | '''40-49''' ||style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center | '''50-59''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center |'''60-69''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center |'''70-83''' | |||
|- | |||
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left | '''No TR (%)''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |14.3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |17.8 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |19 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |18.3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |16.7 | |||
|- | |||
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left | '''Trace (%)''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |72.7 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |72.5 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |71.5 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |59.8 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |47 | |||
|- | |||
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left | '''Mild (%)''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |13 ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left | 9.4 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |9.2 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |21.9 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |25.8 | |||
|- | |||
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left | '''Moderate or severe (%)''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |0 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |0.3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |0.3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |0 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |1.5 | |||
|} | |||
{| | |||
|- | |||
|style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center | '''Severity of TR''' ||style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center colspan=5|'''Prevalence of TR by age in women''' | |||
|- | |||
|style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center| || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center |'''26-29''' ||style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center | '''40-49''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center |'''50-59''' ||style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center | '''60-69''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center |'''70-83''' | |||
|- | |||
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left | '''No TR (%)''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |20.5 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |16 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |14.5 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |10.4 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |14.1 | |||
|- | |||
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left | '''Trace (%)''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |65.1 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |70|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |70.7|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |62.2 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |56.4 | |||
|- | |||
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |'''Mild (%)''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |13.2 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |13.5 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |14.1 ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |25.7 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |23.9 | |||
|- | |||
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |'''Moderate or severe (%)''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |1.2 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |0.5 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |0.7 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |1.7 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |5.6 | |||
|} | |||
==References== | ==References== | ||
Revision as of 15:47, 8 September 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Prevalence
The Framingham Heart Study, a prospective epidemiologic study, evaluated the prevalence and severity of TR and other valvular diseases by color Doppler examinations in 1,696 men and 1,893 women. The study revealed that TR is the second most common valvular regurgitation in the general population, after mitral regurgitation. The prevalence of TR (with a severity ranging from trace to moderate regurgitation) was 82% in men and 85.7% in women. When trace regurgitation is excluded, the prevalence of TR of a severity ≥ mild was 14.8% in men and 18.4% in women. The elevated prevalence of trace regurgitation can be a normal finding related to an artifact or an anatomic characteristic of the closure of the tricuspid valve.[1]
Age
The prevalence of TR increases with age. Shown below are tables depicting the prevalence of MR by age and severity in men and women according the results of the Framingham Heart Study.[1]
| Severity of TR | Prevalence of TR by age in men | ||||
| 26-29 | 40-49 | 50-59 | 60-69 | 70-83 | |
| No TR (%) | 14.3 | 17.8 | 19 | 18.3 | 16.7 |
| Trace (%) | 72.7 | 72.5 | 71.5 | 59.8 | 47 |
| Mild (%) | 13 | 9.4 | 9.2 | 21.9 | 25.8 |
| Moderate or severe (%) | 0 | 0.3 | 0.3 | 0 | 1.5 |
| Severity of TR | Prevalence of TR by age in women | ||||
| 26-29 | 40-49 | 50-59 | 60-69 | 70-83 | |
| No TR (%) | 20.5 | 16 | 14.5 | 10.4 | 14.1 |
| Trace (%) | 65.1 | 70 | 70.7 | 62.2 | 56.4 |
| Mild (%) | 13.2 | 13.5 | 14.1 | 25.7 | 23.9 |
| Moderate or severe (%) | 1.2 | 0.5 | 0.7 | 1.7 | 5.6 |
References
- ↑ 1.0 1.1 Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL; et al. (1999). "Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study)". Am J Cardiol. 83 (6): 897–902. PMID 10190406.